HEALY JAMES 1245624 Data last updated 2024-11-27 07:14:18 -0600 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-22 | 2023-12-13 | 4 | Healy James | DIRECTOR | holding | 42236.0 | 0 | 3.52 | 0.0 | Direct | Common Stock | NATERA, INC. | NA | 120.15 (NTRA) | ||
| 2023-12-22 | 2023-12-13 | 4 | Healy James | DIRECTOR | holding | 1550280.0 | 0 | 129.03 | 0.0 | By Sofinnova Venture Partners Ix, L.P. | Common Stock | NATERA, INC. | NA | 120.15 (NTRA) | ||
| 2023-12-22 | 2023-12-13 | 2023-12-13 | 4 | Healy James | DIRECTOR | dsp | 644000.0 | 100.0 | 53.6 | 58.75 | By Sofinnova Management Viii, L.L.C. | Common Stock | NATERA, INC. | code S | 0.0 | 120.15 (NTRA) |
| 2024-01-30 | 2024-01-26 | 4 | Healy James | DIRECTOR | holding | 1550280.0 | 0 | 129.03 | 0.0 | By Sofinnova Venture Partners Ix, L.P. | Common Stock | NATERA, INC. | NA | 120.15 (NTRA) | ||
| 2024-01-30 | 2024-01-26 | 2024-01-26 | 4 | Healy James | DIRECTOR | acq | 264.0 | 0.62 | 0.02 | 63.79 | Direct | Common Stock | NATERA, INC. | code A | 42500.0 | 120.15 (NTRA) |
| 2024-01-31 | 2024-01-30 | 2024-01-30 | 4 | Healy James | DIRECTOR | acq | 1696752.0 | 100.0 | 4.71 | Sofinnova Venture Partners Xi, L.P. | Common Stock | ARRIVENT BIOPHARMA, INC. | code C P | 1696752.0
|
0.0 (AVBP) | |
| 2024-03-18 | 2024-03-18 | 2024-03-18 | 4 | Healy James | DIRECTOR | dsp | 8025.0 | 100.0 | 2.13 | 330.0 | By Sofinnova Management X, L.P. | Common Stock | KARUNA THERAPEUTICS, INC. | code D | 0.0 | 37.73 (KRTX) |
| 2024-03-18 | 2024-03-18 | 2024-03-18 | 4 | Healy James | DIRECTOR | dsp | 1372441.0 | 100.0 | 363.78 | 330.0 | By Sofinnova Venture Partners X, Lp | Common Stock | KARUNA THERAPEUTICS, INC. | code D | 0.0 | 37.73 (KRTX) |
| 2024-03-18 | 2024-03-18 | 2024-03-18 | 4 | Healy James | DIRECTOR | dsp | 683.0 | 100.0 | 0.18 | 330.0 | By Sofinnova Synergy Master Fund, Lp | Common Stock | KARUNA THERAPEUTICS, INC. | code D | 0.0 | 37.73 (KRTX) |
| 2024-03-18 | 2024-03-18 | 2024-03-18 | 4 | Healy James | DIRECTOR | dsp | 33490.0 | 100.0 | 8.88 | 330.0 | Direct | Common Stock | KARUNA THERAPEUTICS, INC. | code D | 0.0
|
37.73 (KRTX) |
| 2024-04-30 | 2024-04-26 | 4 | Healy James | DIRECTOR | holding | 1550280.0 | 0 | 128.38 | 0.0 | By Sofinnova Venture Partners Ix, L.P. | Common Stock | NATERA, INC. | NA | 120.76 (NTRA) | ||
| 2024-04-30 | 2024-04-26 | 2024-04-26 | 4 | Healy James | DIRECTOR | acq | 210.0 | 0.49 | 0.02 | 0.0 | Direct | Common Stock | NATERA, INC. | code A | 42710.0 | 120.76 (NTRA) |
| 2024-06-10 | 2024-06-10 | 2024-06-10 | 4 | Healy James | DIRECTOR | acq | 17861.0 | 100.0 | 17.0 | By Crestline Summit Master, Spc Crestline Summit Apex Sp | Common Stock | RAPPORT THERAPEUTICS, INC. | code P | 17861.0 | 0.0 (RAPP) | |
| 2024-06-10 | 2024-06-10 | 2024-06-10 | 4 | Healy James | DIRECTOR | acq | 26278.0 | 100.0 | 17.0 | By Crestline Summit Master, Spc Peak Sp | Common Stock | RAPPORT THERAPEUTICS, INC. | code P | 26278.0 | 0.0 (RAPP) | |
| 2024-06-10 | 2024-06-10 | 2024-06-10 | 4 | Healy James | DIRECTOR | acq | 1863327.0 | 100.0 | 4.29 | By Sofinnova Venture Partners Xi, L.P. | Common Stock | RAPPORT THERAPEUTICS, INC. | code C P | 1863327.0
|
0.0 (RAPP) | |
| 2024-06-10 | 2024-06-10 | 2024-06-10 | 4 | Healy James | DIRECTOR | acq | 25455.0 | 100.0 | 17.0 | By Crestline Summit Pinnacle Master, L.P. | Common Stock | RAPPORT THERAPEUTICS, INC. | code P | 25455.0 | 0.0 (RAPP) | |
| 2024-06-10 | 2024-06-10 | 2024-06-10 | 4 | Healy James | DIRECTOR | acq | 18641.0 | 100.0 | 17.0 | By Sofinnova Synergy Master Fund Lp | Common Stock | RAPPORT THERAPEUTICS, INC. | code P | 18641.0 | 0.0 (RAPP) | |
| 2024-06-13 | 2024-06-11 | 2024-06-11 | 4 | Healy James | DIRECTOR | acq | 3495.0 | 11.06 | 0.8 | 0.0 | Direct | Common Stock | Y-MABS THERAPEUTICS, INC. | code A | 31603.0 | 43.88 (YMAB) |
| 2024-06-13 | 2024-06-11 | 4 | Healy James | DIRECTOR | holding | 2194278.0 | 0 | 500.03 | 0.0 | See Footnote F2 | Common Stock | Y-MABS THERAPEUTICS, INC. | NA | 43.88 (YMAB) | ||
| 2024-07-02 | 2024-06-28 | 2024-06-28 | 4 | Healy James | DIRECTOR | acq | 2964.0 | 6.49 | 0.24 | 0.0 | Direct | Common Stock | NATERA, INC. | code A | 45674.0 | 122.8 (NTRA) |
| 2024-07-02 | 2024-06-28 | 4 | Healy James | DIRECTOR | holding | 1550280.0 | 0 | 126.24 | 0.0 | By Sofinnova Venture Partners Ix, L.P. | Common Stock | NATERA, INC. | NA | 122.8 (NTRA) | ||
| 2024-07-03 | 2024-07-01 | 2024-07-01 | 4 | Healy James | DIRECTOR | acq | 14573.0 | 35.67 | 24.52 | By Crestline Summit Master, Spc Peak Sp | Common Stock | RAPPORT THERAPEUTICS, INC. | code P | 40851.0
|
0.0 (RAPP) | |
| 2024-07-03 | 2024-07-01 | 2024-07-01 | 4 | Healy James | DIRECTOR | acq | 14206.0 | 35.82 | 24.52 | By Crestline Summit Pinnacle Master, L.P. | Common Stock | RAPPORT THERAPEUTICS, INC. | code P | 39661.0
|
0.0 (RAPP) | |
| 2024-07-03 | 2024-07-01 | 4 | Healy James | DIRECTOR | holding | 18641.0 | 0 | 0.0 | By Sofinnova Synergy Master Fund Lp | Common Stock | RAPPORT THERAPEUTICS, INC. | NA | 0.0 (RAPP) | |||
| 2024-07-03 | 2024-07-01 | 4 | Healy James | DIRECTOR | holding | 1863327.0 | 0 | 0.0 | By Sofinnova Venture Partners Xi, L.P. | Common Stock | RAPPORT THERAPEUTICS, INC. | NA | 0.0 (RAPP) | |||
| 2024-07-03 | 2024-07-01 | 2024-07-01 | 4 | Healy James | DIRECTOR | acq | 15253.0 | 46.06 | 24.52 | By Crestline Summit Master, Spc Crestline Summit Apex Sp | Common Stock | RAPPORT THERAPEUTICS, INC. | code P | 33114.0
|
0.0 (RAPP) | |
| 2024-07-30 | 2024-07-26 | 2024-07-26 | 4 | Healy James | DIRECTOR | acq | 177.0 | 0.39 | 0.01 | 0.0 | Direct | Common Stock | NATERA, INC. | code A | 45851.0 | 122.8 (NTRA) |
| 2024-07-30 | 2024-07-26 | 4 | Healy James | DIRECTOR | holding | 1550280.0 | 0 | 126.24 | 0.0 | By Sofinnova Venture Partners Ix, L.P. | Common Stock | NATERA, INC. | NA | 122.8 (NTRA) | ||
| 2024-09-27 | 2024-09-25 | 2024-09-27 | 4 | Healy James | DIRECTOR | acq | 21814.0 | 100.0 | 18.0 | Crestline Summit Master, Spc Peak Sp | Common Stock | BIOAGE LABS, INC. | code P | 21814.0 | 0.0 (BIOA) | |
| 2024-09-27 | 2024-09-25 | 2024-09-27 | 4 | Healy James | DIRECTOR | acq | 26497.0 | 100.0 | 18.0 | Crestline Summit Pinnacle Master, L.P. | Common Stock | BIOAGE LABS, INC. | code P | 26497.0 | 0.0 (BIOA) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-25 | 2024-01-25 | 3 | Healy James | DIRECTOR | holding | 1252308.0 | 0 | 0.0 | Sofinnova Venture Partners Xi, L.P. | Series B Preferred Stock | ARRIVENT BIOPHARMA, INC. | NA | 0.0 (AVBP) | |||
| 2024-01-31 | 2024-01-30 | 2024-01-30 | 4 | Healy James | DIRECTOR | dsp | 1252308.0 | 100.0 | 0.0 | Sofinnova Venture Partners Xi, L.P. | Series B Preferred Stock | ARRIVENT BIOPHARMA, INC. | code C | 0.0 | 0.0 (AVBP) | |
| 2024-03-18 | 2024-03-18 | 2024-03-18 | 4 | Healy James | DIRECTOR | dsp | 27904.0 | 100.0 | 7.4 | 222.54 | Direct | Option (Right To Buy) | KARUNA THERAPEUTICS, INC. | code D | 0.0
|
37.73 (KRTX) |
| 2024-06-06 | 2024-06-06 | 3 | Healy James | DIRECTOR | holding | 1392738.0 | 0 | 0.0 | By Sofinnova Venture Partners Xi, L.P. | Series B Preferred Stock | RAPPORT THERAPEUTICS, INC. | NA | 0.0 (RAPP) | |||
| 2024-06-10 | 2024-06-10 | 2024-06-10 | 4 | Healy James | DIRECTOR | dsp | 11924138.0 | 100.0 | 0.0 | By Sofinnova Venture Partners Xi, L.P. | Series B Preferred Stock | RAPPORT THERAPEUTICS, INC. | code C | 0.0 | 0.0 (RAPP) | |
| 2024-06-13 | 2024-06-11 | 2024-06-11 | 4 | Healy James | DIRECTOR | acq | 14545.0 | 100.0 | 3.31 | 12.01 | Direct | Employee Stock Option (Right To Buy) | Y-MABS THERAPEUTICS, INC. | code A | 14545.0 | 43.88 (YMAB) |
| 2024-06-14 | 2024-06-12 | 2024-06-12 | 4 | Healy James | DIRECTOR | acq | 22000.0 | 100.0 | 5.77 | 0.77 | Direct | Stock Option (Right To Buy) | BOLT BIOTHERAPEUTICS, INC. | code A | 22000.0 | 38.13 (BOLT) |
| 2024-09-25 | 2024-09-25 | 3 | Healy James | DIRECTOR | holding | 1638236.0 | 0 | 0.0 | Sofinnova Venture Partners Xi, L.P. | Series D Preferred Stock | BIOAGE LABS, INC. | NA | 0.0 (BIOA) | |||
| 2024-09-27 | 2024-09-25 | 2024-09-25 | 4 | Healy James | DIRECTOR | acq | 15000.0 | 100.0 | 18.0 | Direct | Stock Option (Right To Buy) | BIOAGE LABS, INC. | code A | 15000.0 | 0.0 (BIOA) | |
| 2024-09-27 | 2024-09-25 | 2024-09-27 | 4 | Healy James | DIRECTOR | dsp | 7310796.0 | 100.0 | 0.0 | Sofinnova Venture Partners Xi, L.P. | Series D Preferred Stock | BIOAGE LABS, INC. | code C | 0.0 | 0.0 (BIOA) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)